| | 159351-69-6 Basic information More.. |
| Product Name: | Everolimus | | Synonyms: | Rapamycin, 42-O-(2-hydroxyethyl)-;Everolimus;Certican;CERTICAN(R);EveroliMus(RAD-001);(1R,9S,12S,15R,16Z,18R,19R,21R,23S,24Z,26Z,28Z,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-Methoxycyclohexyl]propan-2-yl]-19,30-diMethoxy-15,17,21,23,29,35-hexaMethyl-11,36-dioxa-4-azatricyclo[30.3.1.0^{4,9}]hexatriaconta-16,2;EveroliMus API;23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, rapamycin deriv | | CAS: | 159351-69-6 | | MF: | C53H83NO14 | | MW: | 958.22 | | EINECS: | 621-003-9 | | Mol File: | 159351-69-6.mol |  |
Use
Everolimus is a derivative of Rapamycin(sirolimus), and works similarly to Rapamycin as an mTOR(mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors, Everolimus takes effect solely on the mTORC1 protein and not on the mTORC2 protein[1]. In transplantation medicine, it is marketed under the trade names Zortress(USA) and Certican(Europe). It has been also used for the treatment of tumors, being marketed as Afinitor(general tumours) and Votubia(tumours as a result of TSC) in oncology.
- Everolimus
-
- US $0.00-0.00 / g
- 2024-04-23
- CAS:159351-69-6
- Min. Order: 1g
- Purity: 99%+
- Supply Ability: 100kgs per Month
- Everolimus
-
- US $0.00 / Kg/Bag
- 2024-04-22
- CAS:159351-69-6
- Min. Order: 2Kg/Bag
- Purity: 0.0099
- Supply Ability: 20 tons
- Everolimus
-
- US $0.00 / kg
- 2024-04-12
- CAS:159351-69-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000ton
|
|
159351-69-6
Recommend Suppliers |
|